Please assess the completion status of the following clinical trial:

Trial Title: Domperidone for Gastroparesis in Solid Organ Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* gastroparesis or gastroesophageal reflux that is refractory to standard therapy.~* signed informed consent~Exclusion Criteria:~* serious cardiac arrhythmias~* clinically significant bradycardia, sinus node dysfunction, or heart block.~* prolonged QTc~* clinically significant electrolyte disorders.~* gastrointestinal hemorrhage or obstruction.~* prolactinoma~* pregnant or breast feeding female~* known allergy to domperidone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Domperidone Arm (Type: EXPERIMENTAL): Study subjects will self-administer oral domperidone 10mg four times a day. If symptoms persist for more than 7 days, the investigator may increase the dose to 20mg four times a day. 20mg four times a day will be the maximal dose. Subjects with signiﬁcant renal impairment will received a starting dose of 10mg twice a day. The maximal dose in subjects with signiﬁcant renal impairment will be 20mg twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).